Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In addition to a number of very compelling clinical observations, an extensive body of extremely supportive experimental data has generated a very persuasive argument that intravenous estrogen should be routinely administered, as soon as possible, to all persons identified as having a critical illness or injury. Although, to date, definitive gold-standard clinical trials are lacking, what has made this provocative argument even more convincing is the longstanding, documented safety of intravenous estrogen for various illnesses and conditions as well as the relative ease and inexpensive cost of treatment. As such, even routine prehospital administration becomes extremely feasible for a myriad of conditions. More importantly, the worldwide magnitude of potential patients who could benefit is profound. Even if estrogen only changes the outcome in a relatively small percentage of applicable cases, the potential impact may still be of dramatic proportions in terms of the absolute number of lives saved and the resources spared worldwide. Resources may be spared not only in terms of diminishing the economic impact of death and long-term disability, but also in terms of preventing extended intensive care unit stays and treatment of preventable complications that result in longer recovery.

Original languageEnglish (US)
JournalCritical Care Medicine
Volume38
Issue number10 SUPPL.
DOIs
StatePublished - Oct 2010

Fingerprint

Critical Illness
Intravenous Administration
Estrogens
Gold
Health Care Costs
Intensive Care Units
Economics
Clinical Trials
Safety
Wounds and Injuries
Therapeutics

Keywords

  • Anti-inflammatory
  • Antiapoptotic
  • Burns
  • Cardiac arrest
  • Cardiopulmonary resuscitation
  • Estrogen
  • Hemorrhagic shock
  • Progesterone
  • Resuscitation
  • Trauma
  • Traumatic brain injury

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

@article{06939b1cdddf4523804a2ce0d5c63001,
title = "Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients",
abstract = "In addition to a number of very compelling clinical observations, an extensive body of extremely supportive experimental data has generated a very persuasive argument that intravenous estrogen should be routinely administered, as soon as possible, to all persons identified as having a critical illness or injury. Although, to date, definitive gold-standard clinical trials are lacking, what has made this provocative argument even more convincing is the longstanding, documented safety of intravenous estrogen for various illnesses and conditions as well as the relative ease and inexpensive cost of treatment. As such, even routine prehospital administration becomes extremely feasible for a myriad of conditions. More importantly, the worldwide magnitude of potential patients who could benefit is profound. Even if estrogen only changes the outcome in a relatively small percentage of applicable cases, the potential impact may still be of dramatic proportions in terms of the absolute number of lives saved and the resources spared worldwide. Resources may be spared not only in terms of diminishing the economic impact of death and long-term disability, but also in terms of preventing extended intensive care unit stays and treatment of preventable complications that result in longer recovery.",
keywords = "Anti-inflammatory, Antiapoptotic, Burns, Cardiac arrest, Cardiopulmonary resuscitation, Estrogen, Hemorrhagic shock, Progesterone, Resuscitation, Trauma, Traumatic brain injury",
author = "Wigginton, {Jane G.} and Pepe, {Paul E.} and Idris, {Ahamed H.}",
year = "2010",
month = "10",
doi = "10.1097/CCM.0b013e3181f243a9",
language = "English (US)",
volume = "38",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients

AU - Wigginton, Jane G.

AU - Pepe, Paul E.

AU - Idris, Ahamed H.

PY - 2010/10

Y1 - 2010/10

N2 - In addition to a number of very compelling clinical observations, an extensive body of extremely supportive experimental data has generated a very persuasive argument that intravenous estrogen should be routinely administered, as soon as possible, to all persons identified as having a critical illness or injury. Although, to date, definitive gold-standard clinical trials are lacking, what has made this provocative argument even more convincing is the longstanding, documented safety of intravenous estrogen for various illnesses and conditions as well as the relative ease and inexpensive cost of treatment. As such, even routine prehospital administration becomes extremely feasible for a myriad of conditions. More importantly, the worldwide magnitude of potential patients who could benefit is profound. Even if estrogen only changes the outcome in a relatively small percentage of applicable cases, the potential impact may still be of dramatic proportions in terms of the absolute number of lives saved and the resources spared worldwide. Resources may be spared not only in terms of diminishing the economic impact of death and long-term disability, but also in terms of preventing extended intensive care unit stays and treatment of preventable complications that result in longer recovery.

AB - In addition to a number of very compelling clinical observations, an extensive body of extremely supportive experimental data has generated a very persuasive argument that intravenous estrogen should be routinely administered, as soon as possible, to all persons identified as having a critical illness or injury. Although, to date, definitive gold-standard clinical trials are lacking, what has made this provocative argument even more convincing is the longstanding, documented safety of intravenous estrogen for various illnesses and conditions as well as the relative ease and inexpensive cost of treatment. As such, even routine prehospital administration becomes extremely feasible for a myriad of conditions. More importantly, the worldwide magnitude of potential patients who could benefit is profound. Even if estrogen only changes the outcome in a relatively small percentage of applicable cases, the potential impact may still be of dramatic proportions in terms of the absolute number of lives saved and the resources spared worldwide. Resources may be spared not only in terms of diminishing the economic impact of death and long-term disability, but also in terms of preventing extended intensive care unit stays and treatment of preventable complications that result in longer recovery.

KW - Anti-inflammatory

KW - Antiapoptotic

KW - Burns

KW - Cardiac arrest

KW - Cardiopulmonary resuscitation

KW - Estrogen

KW - Hemorrhagic shock

KW - Progesterone

KW - Resuscitation

KW - Trauma

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=78650380875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650380875&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e3181f243a9

DO - 10.1097/CCM.0b013e3181f243a9

M3 - Article

C2 - 21164406

AN - SCOPUS:78650380875

VL - 38

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 10 SUPPL.

ER -